

COVID-19 Vaccination in Children 6 Months to 5 Years of Age in Ontario

Statement from paediatric
infectious diseases physicians across Ontario



COVID-19 VACCINATION IN CHILDREN 6 MONTHS TO 5 YEARS OF AGE IN ONTARIO

Key messages:

- COVID-19 vaccination has been approved for use in children 6 months to 5 years of age in Canada. We recommend COVID-19 vaccinations for all children in this age group. We firmly believe that all paediatric health-care providers in Ontario should promote COVID-19 vaccination and encourage caregivers to pursue vaccination for their children aged 6 months to 5 years of age.
- Health-care providers should raise awareness in parents that COVID-19 can cause serious illness in young children even without underlying comorbidity. Although most healthy children have asymptomatic or mild illness, some healthy children may require hospitalization for acute COVID-19 or complications of this infection. To date, there has been 1,441 children aged 0 to 4 years of age who have been hospitalized for COVID-19 in Ontario, corresponding to 202.2 hospitalization per 100,000 children, a rate that is higher than what has been observed in older children, teenagers and young adults aged 20 to 39 years old.
- In the current context of increased circulation of respiratory viruses such as SARS-CoV-2, influenza, and RSV, optimizing the uptake of COVID-19 and influenza vaccines in children are of crucial importance, especially before the winter and holiday season. All children should also be up-to-date on their routine childhood immunizations to provide them with protection against other infectious diseases and complications from respiratory illnesses.
- Safety findings from various monitoring systems in children ages 6 months to 5 years have shown that most reported adverse events are mild, with serious adverse events being rarely reported and no cases of myocarditis/pericarditis having been observed in this age group in Ontario (as of November 6) and the United States (as of August 21).

Background Information: On July 14, 2022, Health Canada approved COVID-19 vaccination for children 6 months to 5 years of age, with the National Advisory Committee on Immunization (NACI) recommending that a primary series of the COVID-19 vaccine be offered to all children in this age group shortly thereafter. However, the proportion of children less than 5 years of age who have been vaccinated against COVID-19 lags considerably behind other age groups. As of November 6, 2022, 7.3% of Ontarian children less than 5 years old have received at least one dose of COVID-19 vaccine, with as few as 2.3% having completed their primary series [1]. In contrast, 52.5% of children 5 to 11 years old received at least one dose, and 83.4% of teenagers 12 to 17 years old received at least one dose.

We recommend COVID-19 vaccinations for all eligible children less than 5 years of age. We firmly believe that all paediatric health-care providers in Ontario should promote COVID-19 vaccination and encourage caregivers to pursue vaccination for their children aged 6 months to 5 years of age. In addition, it is appropriate to address equity issues as this relates to how pediatric vaccination will be promoted and accessed across the socioeconomic spectrum in the province.

The reasons for the significant discrepancy in vaccine uptake that has been observed between children younger than 5 years old and older children are still being examined. Few studies that have assessed caregivers' willingness to vaccinate their children prior to vaccine approval have suggested that parents' perception of COVID-19 severity in children and safety and effectiveness of the vaccine were significantly associated with increased vaccine acceptance [2, 3]. Caregivers' perceptions of vaccine safety may differ by age group, and perceptions of the severity of COVID-19 and vaccine effectiveness have changed compared to when SARS-CoV-2 initially circulated. It is possible that the decreased risk perception of COVID-19 for both children and the population at large has negatively affected vaccine uptake. However, similarly to many other respiratory viruses, young children can develop severe illness from contracting SARS-CoV-2.

To date, there has been 1,441 children aged 0 to 4 years of age who have been hospitalized for COVID-19 in Ontario, corresponding to 202.2 hospitalizations per 100,000 children, a rate that is higher than what has been observed in older children, teenagers and young adults aged 20 to 39 years old [4].

It should be acknowledged that this data also includes infants aged 0 to 6 months old, who are not eligible for COVID-19 vaccination. However, in the United States, 6 months to 4 years old children have also experienced the highest rate of COVID-19-associated hospitalization amongst the pediatric population, with an important increase having been observed since the emergence of Omicron [5]. Further, the number of COVID-19-associated emergency department visits have been comparable between all pediatric age groups (1-4, 5-11 and 12-17 years old), suggesting that young children who contract SARS-CoV-2 have a higher probability of being hospitalized for COVID-19 compared to other age groups [5]. Although most healthy children have asymptomatic or mild illness, some healthy children may require hospitalization for acute COVID-19 or complications of this infection. [6-8].

In the current context and with the anticipated increase in the circulation of these viruses, efforts to mitigate their burden amongst the paediatric population, including through COVID-19 vaccination, are of crucial importance, especially before the winter and the holiday season.

The recent surge of children ill because of respiratory viruses in Ontario, including SARS-CoV-2, influenza, RSV and human metapneumovirus, amongst others, have led to significant pressure on the health-care system. Many hospitals are struggling to deal with far more children admitted to general paediatric wards and intensive care units than would typically be expected, even during the winter season. Other measures to mitigate the burden and

transmission of respiratory viruses such as influenza and RSV include the promotion of influenza vaccination in eligible children and household members, and reinforcing the role of hand hygiene and wearing masks in indoor settings [9-14]. All children should also be up-to-date on their routine childhood immunizations, including the pneumococcal vaccine. This helps to provide them with protection against secondary infectious diseases that might occur as complications from respiratory viral illnesses.

Understandably, caregivers' perception of vaccine effectiveness may also influence their decision to pursue vaccination for their child. Although the effectiveness of monovalent mRNA COVID-19 vaccines has been lower against infection with the Omicron variant compared to infection with previous strains, vaccines do retain moderate to good protection against Omicron-related hospitalization in other age groups [15-19]. In children aged 6 months to 5 years of age, clinical trials showed that vaccines provided protection against COVID-19, including against infection with the Omicron variant [20, 21]. However, studies assessing the real-world vaccine effectiveness in this age group are currently ongoing. Furthermore, caregivers' perspectives of the effectiveness of monovalent COVID-19 vaccines for young children may have also been affected by the recent availability of bivalent vaccines in older age groups, which are expected to have higher effectiveness against Omicron based on immunobridging studies [22]. However, bivalent vaccines have only been studied when administered after an initial primary series of monovalent vaccines, and as such, it is currently recommended that they only be given as booster doses. It is important that children 6 months to 5 years of age complete their primary series with monovalent COVID-19 vaccines before they become eligible for bivalent boosters.

With mRNA COVID-19 vaccines having been broadly administered in adults and older children in the past years, there is an abundance of data reporting on the short and longer-term safety of these vaccines, including clinical trials and various post-marketing surveillance approaches. Safety findings from various monitoring systems in children ages 6 months to 5 years have also shown that most reported adverse events are mild, with serious adverse events being rarely reported [23].

To date, in Ontario, no cases of myocarditis/pericarditis have been observed in children 6 months to 5 years old, amongst 53,363 children who have received at least one dose of the vaccine, and no cases have been observed in the United States as of August 21 [4, 23, 24]. In 5 to 11 year-old children, cases of myocarditis/pericarditis following vaccination have also been extremely rare, with a reporting rate of 5.6 events per one million COVID-19 vaccine doses administered in Ontario; this stands in contrast to what has been observed in 18 to 24 year-old males (109.7 per one million doses) [24].

We are calling for health-care providers and stakeholders to continue their efforts to facilitate access to COVID-19 vaccines in younger children, while addressing ongoing barriers to vaccine access. Several outreach initiatives to increase vaccine access and confidence for adults at higher risk of severe disease were implemented in Ontario during the initial phase of the vaccine rollout, and such initiatives are needed for the paediatric vaccine rollout. Facilitating access to COVID-19 vaccines in settings where childhood immunizations and

influenza vaccines are already being routinely given (primary care clinics, public health units and participating pharmacies) may provide the best opportunity to increase uptake in younger children. Given that it may be challenging for both health-care providers and parents to schedule multiple visits to administer all recommended immunizations in young children, concurrent administration of COVID-19 vaccine and other vaccines may be reasonable at this time in order to facilitate vaccine access. There is no reason to believe that there would be any safety consideration with co-administration in this age group, based on extensive experience in older children and adults.

In light of the points discussed above, joint efforts of paediatric health-care providers in supporting COVID-19 vaccine access and uptake in children aged 6 months to 5 years old will be one of the crucial interventions to maintain the well-being and health of Ontarian children through the upcoming winter.

Available Products:

Comirnaty (Pfizer-BioNTech), three doses (3mcg) 8 weeks apart

Spikevax (Moderna), two doses (25mcg) 8 weeks apart

REFERENCES:

1. Public Health Ontario. COVID-19 Vaccine Uptake in Ontario: December 14, 2020 to November 6, 2022. [Cited 2022 November 17]; Available from: <https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-vaccine-uptake-ontario-epi-summary.pdf>.
2. Mangat C, Rich J, Sanghavi D, Schmidt R, Milosavljevic N, Linh T, et al. Parents' perspective on COVID-19 vaccine in children 6 months through 4 years: a cross-sectional study from Northwest Wisconsin. *BMJ Open*. 2022;12(9):e065453. Epub 2022/09/18. doi: 10.1136/bmjopen-2022-065453. PubMed PMID: 36115680; PubMed Central PMCID: PMC9485653.
3. Hammershaimb EA, Cole LD, Liang Y, Hendrich MA, Das D, Petrin R, et al. COVID-19 Vaccine Acceptance Among US Parents: A Nationally Representative Survey. *J Pediatric Infect Dis Soc*. 2022;11(8):361-70. Epub 2022/06/25. doi: 10.1093/jpids/piac049. PubMed PMID: 35748047; PubMed Central PMCID: PMC9278238.
4. Public Health Ontario. Ontario COVID-19 Data Tool. [Cited 2022 November 17]; Available from: <https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/covid-19-data-surveillance/covid-19-data-tool>.
5. Centers for Disease Control and Prevention (CDC). COVID-19 epidemiology in children ages 6 months–4 years. [Cited 2022 November 17]. Available from: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-06-17-18/02-covid-fleming-dutra-508.pdf>.
6. Whittaker R, Greve-Isdahl M, Boas H, Suren P, Buanes EA, Veneti L. COVID-19 Hospitalization Among Children <18 Years by Variant Wave in Norway. *Pediatrics*. 2022;150(3). Epub 2022/08/03. doi: 10.1542/peds.2022-057564. PubMed PMID: 35916036.
7. Taytard J, Prevost B, Schnuriger A, Aubertin G, Berdah L, Bitton L, et al. SARS-CoV-2 B.1.1.529 (Omicron) Variant Causes an Unprecedented Surge in Children Hospitalizations and Distinct Clinical Presentation Compared to the SARS-CoV-2 B.1.617.2 (Delta) Variant. *Front Pediatr*. 2022;10:932170. Epub 2022/07/15. doi: 10.3389/fped.2022.932170. PubMed PMID: 35832582; PubMed Central PMCID: PMC9271577.
8. Tagarro A, Coya ON, Perez-Villena A, Iglesias B, Navas A, Aguilera-Alonso D, et al. Features of COVID-19 in Children During the Omicron Wave Compared With Previous Waves in Madrid, Spain. *Pediatr Infect Dis J*. 2022;41(5):e249-e51. Epub 2022/03/26. doi: 10.1097/INF.0000000000003482. PubMed PMID: 35333818; PubMed Central PMCID: PMC927014.
9. World Health Organization. Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza; 2019. Licence: CC BY-NC-SA 3.0 IGO. Available from: <https://apps.who.int/iris/bitstream/handle/10665/329439/WHO-WHE-IHM-GIP-2019.1-eng.pdf>.
10. Olson SM, Newhams MM, Halasa NB, Feldstein LR, Novak T, Weiss SL, et al. Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children. *Clin Infect Dis*. 2022;75(2):230-8. Epub 2022/01/14. doi: 10.1093/cid/ciab931. PubMed PMID: 35024795.
11. Kalligeros M, Shehadeh F, Mylona EK, Dapaah-Afryie C, van Aalst R, Chit A, et al. Influenza vaccine effectiveness against influenza-associated hospitalization in children: A systematic review and meta-analysis. *Vaccine*. 2020;38(14):2893-903. Epub 2020/03/03. doi: 10.1016/j.vaccine.2020.02.049. PubMed PMID: 32113808.

12. Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJ, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. *JAMA*. 2010;303(10):943-50. Epub 2010/03/11. doi: 10.1001/jama.2010.250. PubMed PMID: 20215608.
13. Liang M, Gao L, Cheng C, Zhou Q, Uy JP, Heiner K, et al. Efficacy of face mask in preventing respiratory virus transmission: A systematic review and meta-analysis. *Travel Med Infect Dis*. 2020;36:101751. Epub 2020/05/31. doi: 10.1016/j.tmaid.2020.101751. PubMed PMID: 32473312; PubMed Central PMCID: PMCPCMC7253999.
14. Barker J, Stevens D, Bloomfield SF. Spread and prevention of some common viral infections in community facilities and domestic homes. *J Appl Microbiol*. 2001;91(1):7-21. Epub 2001/07/10. doi: 10.1046/j.1365-2672.2001.01364.x. PubMed PMID: 11442709; PubMed Central PMCID: PMCPCMC7166786.
15. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. *JAMA Netw Open*. 2022;5(9):e2232760. Epub 2022/09/23. doi: 10.1001/jamanetworkopen.2022.32760. PubMed PMID: 36136332; PubMed Central PMCID: PMCPCMC9500552.
16. Buchan SA, Nguyen L, Wilson SE, Kitchen SA, Kwong JC. Vaccine Effectiveness of BNT162b2 Against Delta and Omicron Variants in Adolescents. *Pediatrics*. 2022;150(3). Epub 2022/06/17. doi: 10.1542/peds.2022-057634. PubMed PMID: 35706105.
17. Tan SHX, Cook AR, Heng D, Ong B, Lye DC, Tan KB. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age. *N Engl J Med*. 2022;387(6):525-32. Epub 2022/07/21. doi: 10.1056/NEJMoa2203209. PubMed PMID: 35857701; PubMed Central PMCID: PMCPCMC9342421.
18. Gram MA, Emborg HD, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. *PLoS Med*. 2022;19(9):e1003992. Epub 2022/09/02. doi: 10.1371/journal.pmed.1003992. PubMed PMID: 36048766; PubMed Central PMCID: PMCPCMC9436060.
19. Chemaitelly H, AlMukdad S, Ayoub HH, Altarawneh HN, Coyle P, Tang P, et al. Covid-19 Vaccine Protection among Children and Adolescents in Qatar. *N Engl J Med*. 2022. Epub 2022/11/03. doi: 10.1056/NEJMoa2210058. PubMed PMID: 36322837.
20. National Advisory Committee on Immunization [Internet]. Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age. [cited 17 November 2022]. Available from: <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-pfizer-biontech-comirnaty-3-mcg-covid-19-vaccine-children-6-months-4-years.pdf>.
21. National Advisory Committee on Immunization [Internet]. Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age. [cited 17 November 2022]. Available from: <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-moderna-spikevax-covid-19-vaccine-children-6-months-5-years.pdf>.
22. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. *N Engl J Med*. 2022;387(14):1279-91.

Epub 2022/09/17. doi: 10.1056/NEJMoa2208343. PubMed PMID: 36112399; PubMed Central PMCID: PMC9511634.

23. Hause AM, Marquez P, Zhang B, Myers TR, Gee J, Su JR, et al. COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months-5 Years - United States, June 18, 2022-August 21, 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(35):1115-20. Epub 2022/09/02. doi: 10.15585/mmwr.mm7135a3. PubMed PMID: 36048728; PubMed Central PMCID: PMC9472776.

24. Public Health Ontario. Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to November 6, 2022 [Internet]. [Cited 2022 Nov 17]. Available from: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-aei-report.pdf?sc_lang=en.

Drafted by:

Dr Upton Allen, Chief, Division of Infectious Diseases, The Hospital for Sick Children

Dr Pierre-Philippe Piché-Renaud, Division of Infectious Diseases, The Hospital for Sick Children

Dr Jeffrey Pernica, Chief, Division of Infectious Diseases, McMaster Children's Hospital

Dr Michelle Barton-Forbes, Chief, Division of Infectious Diseases, London Health Sciences Centre Children's hospital

Dr Kirk Leifso, Division of Infectious Diseases, Kingston Health Sciences Centre

Dr Charles Hui, Chief, Division of Infectious Diseases, Children's Hospital of Eastern Ontario (CHEO)